PT-141 (Bremelanotide)
The first FDA-approved peptide that works through your brain to reignite sexual desire—think of it as flipping the 'on' switch for arousal rather than just boosting blood flow like traditional ED meds.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Suggested dose
1 – 1.75 mg
Compound profile
PT-141 (Bremelanotide) scientific & efficacy data
Sexual Health
Peptide profile
Strong human trials
PT-141 (Bremelanotide)
1 mg · As needed
Molecular formula
C50H68N14O10
- Mol. weight
- 1025.2 g/mol
- CAS number
- 189691-06-3
- PubChem
- 9941379
- Developed · 2000
- Palatin Technologies research team
Palatin Technologies, Inc.
Amino acid sequence
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OHSexual Desire
FDA approval was based on significant improvements in desire scores and reduced distress over low desire against placebo in two phase 3 trials. [1][7]
On-Demand Use
Used as needed at least 45 minutes before sexual activity, with no daily dosing. How long each dose works is not known. [7]
Clinical Evidence
One of the most thoroughly studied sexual health peptides, with Phase 3 trials, FDA approval, and long-term safety data
Dosing
How much PT-141 (Bremelanotide) do I take?
1 – 1.75 mg
1 – 1.75 mg
Covers all 2 documented dose levels · timing · dose-adjustment guidance.
Every documented dose level
| Phase | Dose | Frequency |
|---|---|---|
| Trial period (assess response/tolerability) | 1 mg | As needed, ~45 min before sexual activity; no more than once per 24 h |
| Ongoing as needed | 1.75 mg | As needed, ~45 min before sexual activity; max once per 24 h and 8 doses per 28 days |
Suitability
Is PT-141 (Bremelanotide) right for me?
Best for restoring sexual desire & treating hypoactive sexual desire disorder (hsdd)
Best for
Women with Low Sexual Desire (HSDD)
PT-141 is FDA-approved specifically for premenopausal women with acquired, generalized hypoactive sexual desire disorder—when you used to have normal desire but it's faded, and it's causing real distress in your life. It's the only approved treatment that works through brain pathways rather than hormones.
Men Who Don't Respond to Viagra-Type Medications
While not FDA-approved for men, clinical research shows PT-141 may help men with erectile dysfunction who don't respond to PDE5 inhibitors like Viagra or Cialis. Because it works through the brain rather than blood vessels, it offers a completely different approach.
Those Wanting On-Demand Treatment
Unlike daily medications like flibanserin (Addyi), PT-141 is used only when you want it—take it 45 minutes before intimacy. This gives you control over timing without committing to daily pills.
People Seeking to Address the 'Wanting' Part of Intimacy
Many sexual health treatments focus on the physical mechanics (blood flow, lubrication). PT-141 is unique because it targets desire itself—the psychological 'wanting' that initiates intimacy. It works on your brain's arousal circuits.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare PT-141 (Bremelanotide) with similar peptides to find the best fit for your goals.
Administration
How do I use PT-141 (Bremelanotide)?
Subcutaneous injection
Route
Subcutaneous injection (just under the skin)—this is how the FDA-approved Vyleesi autoinjector delivers the dose
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is PT-141 (Bremelanotide) safe?
4 common side effects · 2 serious
PT-141 (bremelanotide) was approved by the FDA in 2019 as VYLEESI after two 24-week phase 3 trials in 1,247 premenopausal women.
[1][7] Nausea was the most common reaction (40% vs 1% on placebo): it affected 21% after the first dose and about 3% after later doses, and 8% stopped treatment because of it.
[7] Each dose raises blood pressure by up to 6/3 mmHg, peaking 2–4 hours after the dose, and lowers heart rate by up to 5 beats per minute, usually back to baseline within 12 hours. It is contraindicated in uncontrolled hypertension or known cardiovascular disease.
[7] Focal hyperpigmentation occurred in 1% at up to 8 doses a month. [7] The 52-week open-label extension found no new safety signals. [2]
PT-141 (as Vyleesi) has strong safety data from FDA-required Phase 3 trials and ongoing post-marketing surveillance. It's one of the most thoroughly studied peptides for sexual health. The clinical trials were conducted by Palatin Technologies and AMAG Pharmaceuticals with FDA oversight.
Less common
These typically resolve with continued use or dose adjustment.
Common side effects · experienced by some users
Nausea
The most common side effect: 40% of women in the phase 3 trials, against 1% on placebo. It usually starts within an hour of the dose and lasts about 2 hours, and is most common after the first dose (21%), falling to about 3% with later doses. [7]
Management: Nausea improves for most people with the second dose. [7] Taking ondansetron 30 minutes before the dose did not reduce nausea in a 228-woman study, so the label does not recommend it. [7] For persistent or severe nausea, talk to your prescriber about anti-nausea treatment or stopping. [7]
Facial flushing
About 20% of users experience warmth and redness in the face. This is related to the melanocortin receptors affecting blood vessels.
Management: Usually mild and temporary. In a label study, alcohol did not make flushing more common than bremelanotide alone, though headache was more common with alcohol. [7]
Headache
Reported by about 12% of users, headaches are usually mild and similar to a tension headache.
Management: Stay well-hydrated. Over-the-counter pain relievers like acetaminophen can help if needed. Headaches typically resolve within a few hours.
Injection site reactions
Redness, itching, or minor bruising at the injection site is common with any subcutaneous injection.
Management: Rotate injection sites between abdomen and thighs. Ensure proper technique with clean, appropriate-gauge needles. A cool compress can help.
Stop and seek help if
- Severe nausea that makes the experience unpleasant or affects your health
- Significant blood pressure increases, especially if you feel chest discomfort or severe headache
- Noticeable skin darkening that concerns you (may be irreversible)
- Any signs of allergic reaction—hives, swelling, difficulty breathing
- The medication isn't providing the desired effect after multiple attempts
- You become pregnant or are trying to conceive
PT-141 (Vyleesi) is an FDA-approved medication, but it should be used under healthcare provider supervision. This information is educational—always consult your doctor about starting, stopping, or adjusting any medication. Report any unexpected side effects to your healthcare provider.
With other peptides
- Caution:Melanotan II — Both act on melanocortin receptors. Combining them increases risk of side effects including nausea, blood pressure changes, and hyperpigmentation. Avoid using together.
- Safe:Oxytocin — May complement PT-141 by enhancing emotional bonding aspects of intimacy. Generally considered safe to combine, but research is limited.
- Safe:BPC-157 — No known direct interactions. BPC-157 works on different pathways (healing and gut health). Can likely be used in the same overall protocol.
With medications
- Caution:Blood pressure medications — PT-141 affects blood pressure. Combining with antihypertensives may have unpredictable effects. Use only under medical supervision with monitoring.
- Caution:Oral naltrexone — Bremelanotide can significantly lower oral naltrexone levels. Avoid combining it with naltrexone products for alcohol or opioid addiction, because naltrexone treatment could fail [7]
- Caution:PDE5 inhibitors (Viagra, Cialis) — Both affect cardiovascular parameters. While sometimes combined in research for ED, this should only be done under medical supervision due to additive effects.
- Caution:MAO inhibitors — PT-141 affects dopamine and norepinephrine release. MAOIs can dangerously amplify these effects. Avoid combining.
With supplements
- Safe:Ginger — Can help manage PT-141's nausea side effect. Safe and potentially helpful to take before your dose.
- Safe:Caffeine — Both can affect blood pressure and heart rate. Moderate caffeine is probably fine, but avoid large amounts close to your PT-141 dose.
- Safe:Alcohol — Did not change bremelanotide levels or increase flushing in a label study, but headache was more common with the combination [7]
- Safe:L-arginine — Both affect blood flow mechanisms. No known dangerous interactions, but effects may add up. Monitor how you feel.
Effectiveness
How do I know PT-141 (Bremelanotide) is working?
Strong human trials · first signs first dose (day 1)
Evidence level
Strong human trials
(Phase 3 or FDA approved)
Regulatory status
FDA approved for this use
Onset of effects
Rapid
(hours to days)
How it works
Your brain has special receptors called melanocortin receptors that help control many things, including sexual desire.
PT-141 activates these receptors, particularly one called MC4R, which is found in the part of your brain that controls motivation and reward. When PT-141 turns on these receptors, it triggers the release of dopamine—the 'feel good' chemical that makes you want things.
Unlike Viagra, which just increases blood flow, PT-141 actually works on the 'wanting' part of your brain. It's like turning up the volume on your desire circuit rather than just making the plumbing work better.
The deeper mechanism
Bremelanotide (PT-141) is a synthetic cyclic heptapeptide, Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys)-OH. [7] It is a non-selective melanocortin receptor agonist, with potency in the order MC1R, MC4R, MC3R, MC5R, MC2R; at therapeutic doses MC1R and MC4R binding is most relevant.
[7] MC1R on melanocytes explains the skin darkening. [7] The label states that how it improves desire in HSDD is unknown. [7] Animal studies suggest it may act on presynaptic MC4Rs in the medial preoptic area of the hypothalamus, increasing dopamine release.
[4] Its terminal half-life is about 2.7 hours, and plasma levels peak about 1 hour after injection, with about 100% bioavailability. [7]
What to expect
First dose (Day 1)
What you might notice
- Nausea within 30-60 minutes (most common side effect)
- Facial flushing or feeling warm
- Sexual desire effects beginning around 45-60 minutes
- How long the effect lasts is not known and varies by person [7]
What's normal
- Mild to moderate nausea that resolves on its own
- Warmth in face and chest area
- Gradual increase in feelings of desire or arousal
- Subtle changes—this isn't an instant 'switch flip' for everyone
What's next
- Note your response to gauge future dosing
- If nausea was severe, consider eating beforehand next time
- Wait at least 24 hours before considering another dose
- Many people find effects improve with experience
First few uses
What you might notice
- Nausea often decreases with repeated use
- You learn your optimal timing (some need 60-90 minutes)
- Effects may feel more predictable
- Better understanding of what to expect
What's normal
- Some variation in effect from dose to dose
- Learning what food/timing works best for you
- Mild side effects that are manageable
- Clearer sense of whether PT-141 is working for you
What's next
- Establish your personal protocol based on experience
- Discuss with your healthcare provider if effects are inadequate
- Stay within 8 doses per month maximum
- Monitor for any skin changes with ongoing use
Ongoing use (months)
What you might notice
- Consistent effects if PT-141 works for you
- Tolerance does not appear to develop significantly
- Watch for potential skin hyperpigmentation
- Continued manageable side effects
What's normal
- Stable response pattern over time
- Continued mild nausea/flushing with each dose
- No need to increase dose for same effect
- Possible slight skin darkening in some areas
What's next
- Continue as prescribed by your healthcare provider
- Regular check-ins to assess ongoing benefit vs. side effects
- Report any concerning skin changes
- Reevaluate periodically whether treatment is still needed
Signs it's working
Sexual Desire Indicators
- Increased spontaneous thoughts about intimacy
- Greater interest in initiating sexual activity
- Feeling more 'in the mood' than baseline
- Reduced distress about low desire
- More anticipation or excitement about intimacy
Physical Response Indicators
- Enhanced physical arousal response
- Improved natural lubrication (women)
- Better erectile response (men, off-label use)
- More satisfying intimate experiences overall
- Body feels more 'responsive' to stimulation
Not seeing results? Common reasons
- Not waiting long enough—PT-141 needs at least 45-60 minutes to take effect, some people need 90 minutes
- Nausea overwhelming the experience—try eating a light meal beforehand or starting with a lower dose
- Relationship or psychological factors—PT-141 enhances desire but can't fix underlying relationship issues
- Expectations too high—effects are often subtle and enhance rather than create desire from nothing
- Inconsistent timing—finding your personal 'sweet spot' for timing takes experimentation
- No improvement after 8 weeks — the label says to stop VYLEESI if symptoms have not improved by then [7]
Key research
Clinical trials
PT-141 (Bremelanotide) tested in people
10 registered studies, none currently enrolling.
By phase
A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.
What kind of research
About 2,644 people took part in the studies that actually administered PT-141 (Bremelanotide). Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.
Most recent
Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk
Cosette Pharmaceuticals, Inc.
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
Palatin Technologies, Inc
A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease
Palatin Technologies, Inc
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when PT-141 (Bremelanotide) is named as an intervention; studies that only mention it in passing are not.
Questions
Frequently asked about PT-141 (Bremelanotide)
How is PT-141 different from Viagra or Cialis?
Viagra and Cialis work by increasing blood flow to the genitals—they help with the physical mechanics of arousal but don't affect desire. PT-141 works in your brain, activating receptors that control motivation and wanting. It's the difference between the plumbing working and actually wanting to be intimate in the first place. That's why PT-141 can help people whose bodies work fine but who've lost the 'spark' of desire.
Will PT-141 make me feel aroused all the time?
No—PT-141 enhances your natural desire response rather than creating constant arousal. You'll likely feel more receptive to intimacy and more easily aroused when appropriate situations arise, but you won't be walking around in a constant state of arousal. Think of it as lowering the threshold for desire, not forcing it.
Why does PT-141 cause nausea?
Can men use PT-141?
While PT-141 is only FDA-approved for women with HSDD, research has shown it can help men with erectile dysfunction—particularly those who don't respond to Viagra-type medications. Clinical trials in men have shown positive results, and Palatin Technologies is actively developing it for male ED. Currently, men would be using it off-label.
How often can I use PT-141?
The FDA recommends no more than one dose per 24 hours and no more than 8 doses per month. This isn't about building tolerance (which doesn't seem to happen), but about limiting cumulative side effects like skin hyperpigmentation and ensuring cardiovascular safety.
Will PT-141 darken my skin permanently?
PT-141 can cause focal hyperpigmentation (darkening) of the gums, face, or breasts with repeated use, especially in people with darker skin tones. This is because melanocortin receptors also control skin pigmentation. In some cases, this darkening may not fully reverse. Staying within the recommended 8 doses per month limit helps minimize this risk.
Can I take PT-141 with alcohol?
In a study in the label, alcohol did not change bremelanotide levels. Flushing was no more common than with bremelanotide alone, but headache was more common with the combination. [7] Alcohol can also dampen sexual response, so keeping intake moderate makes sense.
Is the Vyleesi autoinjector the only way to take PT-141?
The FDA-approved form (Vyleesi) comes as a pre-filled autoinjector that's simple to use. However, compounding pharmacies also provide PT-141 as lyophilized powder that you reconstitute and inject yourself with insulin syringes. The active ingredient is the same, but only the Vyleesi autoinjector has FDA approval.
Ready for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for PT-141 (Bremelanotide), on one page.